These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30075958)

  • 1. Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?
    Picard F; Avram R; Marquis-Gravel G; Tadros VX; Ly HQ; Dorval JF; Doucet S; Gosselin G; Asgar AW; Ibrahim R; Bonan R; de Hemptinne Q; Nosair M; L-L'Allier P; Tanguay JF
    Cardiovasc Revasc Med; 2019 Mar; 20(3):228-234. PubMed ID: 30075958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
    Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
    Baumbach A; Zaman A; West NEJ; O'Kane P; Egred M; Johnson T; Wheatcroft S; Bowles R; de Belder A; Bouras G; Lansky A; Hill J; Mathur A; de Belder MA; Banning AP
    EuroIntervention; 2018 Jan; 13(13):1554-1560. PubMed ID: 29131802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience.
    Costopoulos C; Crowson MC; Brown AJ; Braganza DM; Bennett MR; Hoole SP; West NE
    Cardiovasc Revasc Med; 2015 Dec; 16(8):461-4. PubMed ID: 26440767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry.
    Schnorbus B; Wiebe J; Capodanno D; Brugaletta S; Geraci S; Mehilli J; Latib A; Lesiak M; Jensen C; Mattesini A; Münzel T; Capranzano P; Di Mario C; Naber C; Araszkiewicz A; Colombo A; Caramanno G; Sabate M; Tamburino C; Nef H; Gori T
    EuroIntervention; 2017 Oct; 13(9):e1104-e1111. PubMed ID: 28320687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
    Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
    BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.
    Naganuma T; Colombo A; Lesiak M; Capodanno D; Gori T; Nef H; Caramanno G; Naber C; Di Mario C; Ruparelia N; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Kawamoto H; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Latib A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):47-56. PubMed ID: 27414021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry.
    Cortese B; di Palma G; Cerrato E; Latini RA; Elwany M; Orrego PS; Seregni RG
    J Interv Cardiol; 2017 Oct; 30(5):427-432. PubMed ID: 28853189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry.
    Moscarella E; Ielasi A; Varricchio A; Cortese B; Loi B; Tarantini G; Pisano F; Durante A; Pasquetto G; Colombo A; Tumminello G; Moretti L; Calabrò P; Mazzarotto P; Tespili M; Silva Orrego P; Corrado D; Steffenino G;
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):404-410. PubMed ID: 30346080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.